Joop van Gerven (1958) studied English and Medicine in Utrecht University. After obtained his MD in 1984, he worked in the Department of Internal Medicine of Leiden University Medical Center (LUMC). In 1990 he completed a PhD-thesis on aldose reductase inhibitor treatment in diabetes mellitus. He was trained as a neurologist in Dijkzigt University Hospital in Rotterdam from 1988 to 1994. During that period, he was also a consultant for Wyeth on diabetic complications. Since 1994 he is director CNS research at the Centre for Human Drug Research (CHDR) in Leiden, and is responsible for consultancy and research on central nervous system drugs and methods. He is also clinically active as a staff consultant neurologist at LUMC. Since 2004 he is Professor of Clinical Psychoneuropharmacology at Leiden University. His primary interest is in the prediction of pharmacological effects of CNS-active agents during early phases of drug development, and in neuropsychiatric challenge-tests. He has published roughly 130 peer reviewed articles and book chapters and is supervisor (‘promotor’) of about ten PhD-projects in these areas. Joop van Gerven is the clinical pharmacologist of the CCMO, the Dutch competent authority and central ethics committee for research in human subjects.